We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+23.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.11B
AUM Growth
+$195M
Cap. Flow
+$57.8M
Cap. Flow %
5.19%
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$49.7M
2
ENDP
Endo International plc
ENDP
+$46.9M
3
ALR
Alere Inc
ALR
+$29.1M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$27.8M
5
BIIB icon
Biogen
BIIB
+$21.5M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$45.4M
2
CELG
Celgene Corp
CELG
+$38.3M
3
GILD icon
Gilead Sciences
GILD
+$34.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
5
AZN icon
AstraZeneca
AZN
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.46%
2 Miscellaneous 10.8%
3 Financials 2.03%
4 Technology 1.63%
5 Communication Services 1.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WOOF icon
26
DELISTED
VCA Inc.
WOOF
$16.9M 1.52%
+307,804
New +$16.1M
2015 Q1
0 quarters
TRIV
27
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$16.7M 1.5%
1,588,623
-166,945
-10% -$1.72M
2014 Q2
3 quarters
PRQR icon
28
ProQR Therapeutics
PRQR
$203M
$16.4M 1.48%
751,171
– –
2014 Q3
2 quarters
HNT
29
DELISTED
HEALTH NET INC
HNT
$16.4M 1.47%
270,358
-38,687
-13% -$2.18M
2014 Q3
2 quarters
ITCI icon
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16M 1.43%
668,671
-322,139
-33% -$7.22M
2014 Q1
4 quarters
GMED icon
31
Globus Medical
GMED
$10.5B
$15.4M 1.39%
611,731
– –
2013 Q2
7 quarters
CLDX icon
32
Celldex Therapeutics
CLDX
$2.25B
$15.2M 1.37%
36,467
+34,727
+1,996% +$12.4M
2014 Q4
1 quarter
ARAY icon
33
Accuray
ARAY
$20.3M
$14.1M 1.27%
1,515,475
-20,000
-1% -$159K
2013 Q3
6 quarters
ABUS icon
34
Arbutus Biopharma
ABUS
$840M
$12.2M 1.1%
+700,000
New +$14.3M
2015 Q1
0 quarters
KYTH
35
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$11.3M 1.01%
+225,062
New +$9.45M
2015 Q1
0 quarters
ATRA icon
36
Atara Biotherapeutics
ATRA
$93.1M
$11M 0.99%
10,608
+37
+0.4% +$24.5K
2014 Q4
1 quarter
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$11M 0.99%
1,077,642
-188,896
-15% -$2.32M
2013 Q3
6 quarters
NVTA
38
DELISTED
Invitae Corporation
NVTA
$10.9M 0.98%
+785,131
New +$14.5M
2015 Q1
0 quarters
GWPH
39
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$10.9M 0.97%
+119,114
New +$9.67M
2015 Q1
0 quarters
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.45M 0.85%
+99,613
New +$7.03M
2015 Q1
0 quarters
BLCM
41
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9.28M 0.83%
44,522
-41,559
-48% -$10.1M
2014 Q4
1 quarter
NUVA
42
DELISTED
NuVasive, Inc.
NUVA
$8.51M 0.76%
185,137
-173,542
-48% -$8.06M
2013 Q2
7 quarters
CERS icon
43
Cerus
CERS
$457M
$6.87M 0.62%
+1,647,727
New +$8.44M
2015 Q1
0 quarters
OPCH icon
44
Option Care Health
OPCH
$4.66B
$6.11M 0.55%
+344,550
New +$7.52M
2015 Q1
0 quarters
FLXN icon
45
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.27M 0.38%
189,624
-125,520
-40% -$2.91M
2014 Q1
4 quarters
AKAO
46
DELISTED
Achaogen Inc
AKAO
$3.89M 0.35%
398,340
-335,613
-46% -$3.78M
2014 Q1
4 quarters
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.79M 0.25%
+78,972
New +$2.7M
2015 Q1
0 quarters
CARM icon
48
DELISTED
Carisma Therapeutics
CARM
$2.14M 0.19%
12,000
– –
2014 Q4
1 quarter
IHF icon
49
iShares US Healthcare Providers ETF
IHF
$1.44B
$1.14M 0.1%
42,995
+30,495
+244% +$761K
2014 Q3
2 quarters
PPH icon
50
VanEck Pharmaceutical ETF
PPH
$1.08B
$457K 0.04%
6,500
– –
2013 Q2
7 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2015 Portfolio in Review

As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.

  • Redmile Group's largest Q1 2015 buy was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.
  • Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
  • Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
  • Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
  • Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
  • Redmile Group opened 18 new positions and closed 18 in Q1 2015.
  • Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.